Welcome to our dedicated page for Aclarion news (Ticker: ACON), a resource for investors and traders seeking the latest updates and insights on Aclarion stock.
Aclarion, Inc. (NASDAQ: ACON) is a leading healthcare technology company specializing in the innovative use of Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. Their flagship product, Nociscan, is a unique Software as a Service (SaaS) platform that noninvasively assists physicians in distinguishing between painful and nonpainful discs in the spine. By leveraging advanced MRS technology, Nociscan helps to identify the specific source of chronic low back pain (cLBP), a condition affecting 266 million people globally.
Nociscan generates reports based on MRS data collected from MRI machines, quantifying chemical biomarkers associated with disc pain. This data enables physicians to tailor treatment strategies optimally. The company derives its revenue primarily from the delivery of these Nociscan reports to medical professionals across the United States, enhancing their ability to make informed clinical decisions.
Recent developments highlight the company’s accelerated growth and significant milestones. Aclarion recently completed its 1,000th commercial Nociscan exam, marking an exciting phase of adoption. Moreover, the company is expanding Nociscan's compatibility beyond Siemens MRI machines, increasing its accessibility worldwide. The strategic partnership with Alphatec Spine, Inc. aims to integrate Nociscan into ATEC's AlphaInformatiX platform, providing comprehensive data to improve surgical decision-making for spine surgery.
The company is also initiating the pivotal multicenter, prospective, randomized CLARITY trial to validate superior surgical outcomes when Nociscan is integrated into surgical decision processes. Furthermore, Aclarion’s involvement in the LIFEHAB Trial in Norway underscores its commitment to advancing scientific understanding of chronic low back pain and improving patient outcomes.
Aclarion’s innovative approach is well-supported by a robust patent portfolio, including 22 U.S. patents and numerous international patents. The company's mission is to set a new standard of care in spinal diagnostics by offering noninvasive, data-driven insights that enhance the effectiveness of low back pain treatments.
Aclarion (Nasdaq: ACON) has secured its first commercial agreement with Scripps Health in San Diego, expanding access to its Nociscan technology. The agreement brings the diagnostic solution to Southern California's largest healthcare system, serving over 3.2M people in the San Diego Metro area.
Nociscan, which uses MR Spectroscopy and AI to identify chronic low back pain sources, will be available at Scripps Green Hospital. Dr. Robert Eastlack, Orthopedic Surgeon at Scripps Health, emphasized the technology's value in providing additional diagnostic information for patients previously referred to Beverly Hills for the procedure.
Scripps Health operates five hospitals and 19 outpatient facilities, treating 500,000 patients annually through 2,600 affiliated physicians. The system will implement Nociscan both in clinical practice and research trials, supporting their mission to advance spine care.
Aclarion (NASDAQ: ACON), a healthcare technology company specializing in MRS and AI for back and neck pain treatment optimization, has announced the adjournment of its Special Meeting of Stockholders originally scheduled for February 28, 2025.
The meeting has been rescheduled to March 5, 2025, at 9:30 a.m. Mountain Time at the company's Broomfield, Colorado office. The adjournment aims to solicit additional votes for proposals outlined in the company's proxy statement filed with the SEC on February 3, 2025.
The record date remains January 6, 2025. Previously submitted proxies will remain valid unless revoked. Shareholders can modify their votes until 11:59 p.m. Mountain Time on March 4, 2025, either through Internet voting or by submitting a new signed proxy.
Aclarion (Nasdaq: ACON) announced its participation in the 2025 Spine Summit, where Dr. Nicholas Theodore will showcase the company's NOCISCAN technology. NOCISCAN is a pioneering SaaS platform that combines MR Spectroscopy with augmented intelligence to help physicians identify the location of chronic low back pain.
Dr. Theodore, who serves as Professor at Johns Hopkins University School of Medicine and holds multiple director positions, will present 'NOCISCAN, Augmented Intelligence, and Low Back Pain Decision Support' on February 21, 2025. The technology is particularly significant given that approximately 266 million people worldwide suffer from degenerative spine disease and low back pain.
NOCISCAN is the first evidence-supported platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine by objectively quantifying chemical biomarkers associated with disc pain.
Aclarion (NASDAQ: ACON) has received its 24th US patent through a Notice of Allowance from the USPTO. This patent expands the company's ability to use Magnetic Resonance Spectroscopy (MRS) for identifying propionic acid (PA) throughout the body as a potential biomarker for infection and pain. Previously, Aclarion's patents PA identification by MRS to intervertebral discs only.
The company's technology leverages MRS, a capability of common MRI scanners, to analyze chemical biomarkers within soft tissues. While traditional MRS post-processing faces challenges in generating quality data, Aclarion's patented innovations address these limitations, ensuring more reliable spectral data analysis for their Nociscan solution and other MRS applications.
Aclarion (NASDAQ: ACON) has announced Northwestern Medicine as the first site for its pivotal CLARITY trial, designed to demonstrate Nociscan's clinical and economic value in spine surgery. Northwestern Medicine, which led over 6,900 clinical studies with 372,561 participants in 2024, will participate in this groundbreaking randomized controlled trial.
The CLARITY trial is a fully funded, prospective, multi-center study that will evaluate 300 patients scheduled for surgical treatment of 1- or 2-level discogenic low back pain. The study will compare surgical outcomes between surgeons who are blinded and unblinded to Nociscan results. Nociscan is the first evidence-supported SaaS platform that helps physicians distinguish between painful and nonpainful discs in the lumbar spine through MR Spectroscopy and AI technology.
Aclarion (NASDAQ: ACON) has secured nearly $20 million in gross proceeds in 2025 to fully fund its pivotal CLARITY trial, a prospective, randomized, multicenter study designed to validate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain patients.
The CLARITY trial, led by Dr. Nicholas Theodore of Johns Hopkins, will enroll 300 patients across multiple sites. Nociscan is the first evidence-supported SaaS platform that helps physicians identify painful discs in the lumbar spine through MR Spectroscopy and AI, showing a 97% surgical success rate at one-year follow-up when all Nociscan-identified pain-positive discs are treated.
The technology addresses a significant global healthcare challenge, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain.
Aclarion (NASDAQ: ACON) announced its participation in the Selby Spine Conference, where Dr. Sigurd Berven will present the company's NOCISCAN platform. The presentation, titled 'MR Spectroscopy, Augmented Intelligence, and Low Back Pain – A New Gold Standard,' will showcase how NOCISCAN combines MR Spectroscopy with AI to help physicians identify biomarkers associated with disc pain that are invisible on traditional MRI scans.
NOCISCAN is the first evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. This technology addresses a significant global healthcare challenge, as approximately 266 million people worldwide suffer from degenerative spine disease and low back pain. The presentation is scheduled for January 31, 2025, at 5:55 PM in Deer Valley, UT.
Aclarion (NASDAQ: ACON) announced that its Nociscan product is featured in the RSNA Edition of Siemens Healthineers magazine, MAGNETOM Flash. The article showcases how physicians incorporate Nociscan into their clinical practices for chronic low back pain patients. Nociscan is the first evidence-supported SaaS platform that helps physicians noninvasively distinguish between painful and nonpainful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain. The feature will be highlighted at the RSNA annual meeting from December 1-4, 2024, and is expected to serve as a valuable reference for the medical community.
Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis through biomarkers and AI algorithms, has announced its participation in the upcoming Virtual Investor Summit Microcap Event on November 21st, 2024. The company will deliver a presentation from 3:30 PM to 4:00 PM ET and will be available for one-on-one meetings throughout the day.
The event will showcase 40 micro-cap companies with catalysts and strong market performance. The presentation will be accessible via webcast, and qualified investors can register for complimentary access to participate in live Q&A sessions.
Aclarion (Nasdaq: ACON, ACONW), a healthcare technology company specializing in chronic low back pain location identification through biomarkers and AI algorithms, has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The event, presented by Maxim Group , is scheduled for October 15, 2024.
CEO Brent Ness will represent Aclarion in a fireside chat at 2:00 PM ET. The summit will feature presentations and interactive discussions with CEOs and key management from various healthcare sectors, including biotechnology, diagnostics, medical devices, and healthcare information technology.
Maxim senior analysts will host these sessions, providing insights into the participating companies. Interested parties can reserve their seats for the virtual event through a provided link.
FAQ
What is the current stock price of Aclarion (ACON)?
What is the market cap of Aclarion (ACON)?
What does Aclarion, Inc. do?
What is Nociscan?
How does Aclarion generate revenue?
What recent achievements has Aclarion made?
What is the CLARITY trial?
What partnerships has Aclarion formed?
What is the significance of Nociscan's compatibility with different MRI machines?
What is the LIFEHAB trial?
How does Nociscan improve surgical outcomes?
What is Aclarion's patent portfolio like?
